Medicines' Oritavancin Strong In Confirmatory Phase III Trial
By Randy Osborne
Tuesday, July 2, 2013
Another set of positive Phase III data with oritavancin, a semi-synthetic lipoglycopeptide antibiotic, in acute bacterial skin and skin structure infections puts The Medicines Co. in line for a 2014 approval, and possibly a partnership to help commercialize the compound, which treats disorders caused by susceptible gram-positive bugs that include methicillin-resistant Staphylococcus aureus.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.